LENSAR, Inc. (LNSR)
Market Cap | 166.59M |
Revenue (ttm) | 53.49M |
Net Income (ttm) | -31.40M |
Shares Out | 11.79M |
EPS (ttm) | -2.73 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 172,381 |
Open | 14.17 |
Previous Close | 14.14 |
Day's Range | 14.13 - 14.20 |
52-Week Range | 2.67 - 17.31 |
Beta | 0.62 |
Analysts | Hold |
Price Target | 15.00 (+6.16%) |
Earnings Date | May 8, 2025 |
About LNSR
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System. The company offers LENSAR Laser System which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment s... [Read more]
Financial Performance
In 2024, LENSAR's revenue was $53.49 million, an increase of 26.87% compared to the previous year's $42.16 million. Losses were -$31.40 million, 118.3% more than in 2023.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for LNSR stock is "Hold" and the 12-month stock price forecast is $15.0.
News

LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of LENSA...

LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ORLANDO, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR's board of directors gran...

LENSAR, Inc. (LNSR) Q4 2024 Earnings Call Transcript
LENSAR, Inc. (NASDAQ:LNSR) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Cameron Radinovic - Investor Relations, Burns McClellan Nicholas Curtis - Chief Executive...

LENSAR Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
31 ALLY Robotic Cataract Laser Systems™ placed in Q4 2024, representing an 86% increase in ALLY placements in full year 2024 over 2023; Company's total installed systems increased to approximately 385...

LENSAR to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 27, 2025
ORLANDO, Fla., Feb. 19, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced robotic laser solutions for the treatm...

Medical Devices Firm Lensar Surges Ahead On Robotic Technology
LENSAR, Inc. is rated a Strong Buy by the Quant system, Wall Street analysts, and me, due to its innovative cataract treatment technology and growing market share. The company's ALLY Robotic Cataract ...

LENSAR to Participate in the BTIG 4th Annual Ophthalmology Day
ORLANDO, Fla., Nov. 26, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced robotic laser solutions for the treatm...

LENSAR, Inc. (LNSR) Q3 2024 Earnings Call Transcript
LENSAR, Inc. (NASDAQ:LNSR) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Cameron Radinovic - Investor Relations, Burns McClellan Nicholas Curtis - Chief Executive ...

LENSAR Reports Third Quarter 2024 Results and Provides Business Update
24 ALLY Robotic Laser Cataract Systems™ placed in 3Q 2024 including 11 sales in EU and Southeast Asia; Robust backlog with 24 systems pending installation as of September 30, 2024

LENSAR to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024
ORLANDO, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced robotic laser solutions for the treatm...

One Millionth Procedure Completed Using LENSAR's Cataract Laser Systems
ORLANDO, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatm...

LENSAR to Participate in Two Upcoming Investor Conferences
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR®, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today ...

LENSAR, Inc. (LNSR) Q2 2024 Earnings Call Transcript
LENSAR, Inc. (NASDAQ:LNSR) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Cameron Radinovic - IR Nicholas Curtis - CEO & Director Thomas Staab - CFO Conference Call P...

LENSAR Reports Second Quarter 2024 Results and Provides Business Update
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR®, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today ...

LENSAR Announces Certification for the ALLY® Adaptive Cataract Treatment System in the European Union
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today a...

LENSAR to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today a...

LENSAR to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of catara...

LENSAR, Inc. (LNSR) Q1 2024 Earnings Call Transcript
LENSAR, Inc. (NASDAQ:LNSR) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Lee Roth - Burns McClellan Nicholas Curtis - CEO Thomas Staab - CFO Conference Call Participant...

LENSAR Reports First Quarter 2024 Results and Provides Business Update
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of catara...

LENSAR to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of catara...

LENSAR, Inc. (LNSR) Q4 2023 Earnings Call Transcript
LENSAR, Inc. (NASDAQ:LNSR) Q4 2023 Earnings Conference Call March 4, 2024 8:30 AM ET Company Participants Cameron Radinovic - Burns McClellan Nicholas Curtis - Chief Executive Officer Thomas Staab - ...

LENSAR Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of catara...

LENSAR to Report Fourth Quarter and Full Year 2023 Financial Results on Monday, March 4, 2024
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of catara...

LENSAR, Inc. (LNSR) Q3 2023 Earnings Call Transcript
LENSAR, Inc. (NASDAQ:LNSR) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Cameron Radinovic - Burns McClellan Nicholas Curtis - CEO Thomas Staab - CFO Conference Ca...

LENSAR Reports Third Quarter 2023 Results and Provides Business Update
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of catara...